Clinical Trials Browser

Phase 1/2 × INDUSTRY × dabrafenib × Clear all

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02130466 2022-08-01

MK-3475-022

Phase 1/2 Completed

184 enrolled 62 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01677741 2021-11-24

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Phase 1/2 Completed

85 enrolled 25 charts

Brain Neoplasms

NCT01750918 2021-10-29

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

Phase 1/2 Completed

166 enrolled 46 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT02124772 2021-07-14

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Phase 1/2 Completed

139 enrolled 42 charts 1 FDA

Histiocytosis, Langerhans-Cell, Neoplasms, Neuroblastoma, Neurofibroma, Plexiform

NCT03391050 2019-07-31

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Phase 1/2 Terminated

Melanoma, Neoplasm Metastasis, Skin Neoplasms